PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Present at Cantor Fitzgerald Global Healthcare Conference
DURHAM, N.C. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix, will present a corporate
View HTML
Toggle Summary Chimerix Appoints Heather Knight-Trent, PharmD, as Vice President of Regulatory Affairs
DURHAM, N.C. , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced the appointment of Heather Knight-Trent , PharmD, as Vice
View HTML
Toggle Summary Chimerix Announces Second Quarter 2017 Financial Results
- Conference Call at 8:30 a.m. ET Today -
View HTML
Toggle Summary Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017
DURHAM, N.C., July 31, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on
View HTML
Toggle Summary Chimerix Announces First Quarter 2017 Financial Results
- Conference Call at 8:30 a.m. ET Today -
View HTML
Toggle Summary Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017
DURHAM, N.C. , May 02, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on
View HTML
Toggle Summary Chimerix to Host Annual Investor Update on April 27, 2017
DURHAM, N.C. , April 20, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host the Company's annual investor update event
View HTML
Toggle Summary Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results
- Successful Administration of IV Brincidofovir 50 mg in Ongoing Dose Escalation Study - - Demonstrates Favorable Safety and Tolerability Profile - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , March 02, 2017 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 37th Annual Health Care Conference
DURHAM, N.C. , Feb. 28, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and   commercializing medicines that address significant, unmet medical needs, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of
View HTML
Toggle Summary Chimerix to Announce Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
DURHAM, N.C. , Feb. 23, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company committed to discovering, developing and commercializing medicines that address significant, unmet medical needs, today announced that it will host a live conference call and audio webcast on
View HTML